At present, a variety of assessment models have been developed based on serum CA125 and (or) HE4 levels combined with indicators including patient’s menopausal status to predict the risk of ovarian cancer in patients with suspected benign ovarian tumors, showing good diagnostic value (5). This evidence concerns the gene MUC16 and ovarian carcinoma.